<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Abbvie Inc — News on 6ix</title>
<link>https://6ix.com/company/abbvie-inc</link>
<description>Latest news and press releases for Abbvie Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 16:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/abbvie-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683540ac0eaa31f6af967762.webp</url>
<title>Abbvie Inc</title>
<link>https://6ix.com/company/abbvie-inc</link>
</image>
<item>
<title>AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus</title>
<link>https://6ix.com/company/abbvie-inc/news/abbvie-selects-north-carolina-for-new-dollar14-billion-manufacturing-campus</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/abbvie-selects-north-carolina-for-new-dollar14-billion-manufacturing-campus</guid>
<pubDate>Wed, 22 Apr 2026 16:00:00 GMT</pubDate>
<description>AbbVie (NYSE: ABBV) today announced a $1.4 billion investment to build a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina. The state-of-the-art campus will integrate advanced manufacturing and laboratory technologies with artificial intelligence (AI) to support the production of AbbVie's immunology, neuroscience and oncology medicines.</description>
</item>
<item>
<title>Middle East and Africa Biosimilars Market Trends Report 2026-2035, Profiles of AbbVie, Amgen, Biocon, Celltrion, Dr. Reddy's, Pfizer, Roche, Samsung, Sandoz, Teva, Viatris</title>
<link>https://6ix.com/company/abbvie-inc/news/middle-east-and-africa-biosimilars-market-trends-report-2026-2035-profiles-of-abbvie-amgen-biocon-celltrion-dr-reddys-pfizer-roche-samsung-sandoz-teva-viatris</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/middle-east-and-africa-biosimilars-market-trends-report-2026-2035-profiles-of-abbvie-amgen-biocon-celltrion-dr-reddys-pfizer-roche-samsung-sandoz-teva-viatris</guid>
<pubDate>Fri, 17 Apr 2026 10:17:00 GMT</pubDate>
<description>The Middle East and Africa biosimilars market is poised for strong growth due to patent expiries, increased chronic disease prevalence, and supportive regulations. High demand for affordable biologics, especially for oncological and chronic conditions, presents significant market opportunities amidst challenges like high development costs and regulatory complexities. Middle Eastern and African Biosimilars Market Middle Eastern and African Biosimilars Market Dublin, April 17, 2026 (GLOBE NEWSWIRE</description>
</item>
<item>
<title>Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain</title>
<link>https://6ix.com/company/abbvie-inc/news/haisco-enters-into-exclusive-license-agreement-with-abbvie-to-develop-novel-medicines-for-pain</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/haisco-enters-into-exclusive-license-agreement-with-abbvie-to-develop-novel-medicines-for-pain</guid>
<pubDate>Mon, 13 Apr 2026 06:24:00 GMT</pubDate>
<description>On April 10, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV), a global biopharmaceutical company. Under the agreement, Haisco grants AbbVie the exclusive rights to develop, manufacture, and commercialize novel medicines for the treatment of pain globally, excluding mainland China, Hong Kong, and Macau.</description>
</item>
<item>
<title>AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026</title>
<link>https://6ix.com/company/abbvie-inc/news/abbvie-showcases-latebreaking-phase-2-data-for-mirvetuximab-soravtansine-gynx-elaherer-in-platinumsensitive-ovarian-cancer-psoc-at-sgo-2026</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/abbvie-showcases-latebreaking-phase-2-data-for-mirvetuximab-soravtansine-gynx-elaherer-in-platinumsensitive-ovarian-cancer-psoc-at-sgo-2026</guid>
<pubDate>Sun, 12 Apr 2026 11:15:00 GMT</pubDate>
<description>AbbVie (NYSE: ABBV) today announced that late-breaking results from the Phase 2 IMGN853-0420 trial will be presented in an oral session at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting (San Juan, Puerto Rico; April 10-13, 2026). The study evaluated the potential efficacy and safety of mirvetuximab soravtansine-gynx, a first-in-class antibody-drug conjugate (ADC), in combination with carboplatin followed by maintenance of mirvetuximab soravtansine-gynx monotherapy, in patients wit</description>
</item>
<item>
<title>/C O R R E C T I O N -- AbbVie/</title>
<link>https://6ix.com/company/abbvie-inc/news/c-o-r-r-e-c-t-i-o-n-abbvie</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/c-o-r-r-e-c-t-i-o-n-abbvie</guid>
<pubDate>Tue, 31 Mar 2026 14:04:00 GMT</pubDate>
<description>Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced its fourth annual CoolMonth, featuring exclusive offers on CoolSculpting®, the treatment doctors use most for nonsurgical fat reduction.1</description>
</item>
<item>
<title>AbbVie to Host First-Quarter 2026 Earnings Conference Call</title>
<link>https://6ix.com/company/abbvie-inc/news/abbvie-to-host-first-quarter-2026-earnings-conference-call</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/abbvie-to-host-first-quarter-2026-earnings-conference-call</guid>
<pubDate>Tue, 31 Mar 2026 12:00:00 GMT</pubDate>
<description>AbbVie (NYSE: ABBV) will announce its first-quarter 2026 financial results on Wednesday, April 29, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.</description>
</item>
<item>
<title>AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting</title>
<link>https://6ix.com/company/abbvie-inc/news/abbvie-to-highlight-new-clinical-and-real-world-evidence-advancing-standards-of-care-in-immune-mediated-skin-diseases-at-the-2026-aad-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/abbvie-to-highlight-new-clinical-and-real-world-evidence-advancing-standards-of-care-in-immune-mediated-skin-diseases-at-the-2026-aad-annual-meeting</guid>
<pubDate>Fri, 27 Mar 2026 14:00:00 GMT</pubDate>
<description>AbbVie (NYSE: ABBV) today announced new research across its dermatology portfolio to be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, March 27–31 in Denver, Colorado.</description>
</item>
<item>
<title>AbbVie Named Official Pharmaceutical Partner of Major League Baseball</title>
<link>https://6ix.com/company/abbvie-inc/news/abbvie-named-official-pharmaceutical-partner-of-major-league-baseball</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/abbvie-named-official-pharmaceutical-partner-of-major-league-baseball</guid>
<pubDate>Tue, 24 Mar 2026 12:00:00 GMT</pubDate>
<description>AbbVie (NYSE: ABBV) today announced a multi-year partnership with Major League Baseball (MLB), naming AbbVie the Official Pharmaceutical Partner of MLB beginning with the 2026 season. This partnership, a first-of-its-kind for the company, marks the national expansion of Striking Out Cancer - first introduced during the 2025 MLB season through AbbVie's collaboration with the Chicago Cubs, which enters its second year in the 2026 season. This new partnership extends Striking Out Cancer beyond AbbV</description>
</item>
<item>
<title>AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults</title>
<link>https://6ix.com/company/abbvie-inc/news/abbvie-announces-positive-topline-results-from-a-phase-1-multiple-ascending-dose-study-of-abbv-295-a-long-acting-amylin-analog-in-adults</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/abbvie-announces-positive-topline-results-from-a-phase-1-multiple-ascending-dose-study-of-abbv-295-a-long-acting-amylin-analog-in-adults</guid>
<pubDate>Mon, 09 Mar 2026 12:00:00 GMT</pubDate>
<description>AbbVie (NYSE: ABBV) today announced positive topline results1 from the multiple ascending dose (MAD) part of its Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous ABBV-295, in adults with a mean body mass index (BMI) of less than 30 kg/m2. ABBV-295 is a long-acting amylin analog that represents a mechanistically distinct class from incretin-based therapies such as GLP-1 and GIP receptor agonists.</description>
</item>
<item>
<title>AbbVie to Present at the Leerink Partners Global Healthcare Conference</title>
<link>https://6ix.com/company/abbvie-inc/news/abbvie-to-present-at-the-leerink-partners-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/abbvie-to-present-at-the-leerink-partners-global-healthcare-conference</guid>
<pubDate>Tue, 03 Mar 2026 13:00:00 GMT</pubDate>
<description>AbbVie (NYSE: ABBV) will participate in the Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026. Management will participate in a fireside chat at 10:20 a.m. Central Time.</description>
</item>
<item>
<title>AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease</title>
<link>https://6ix.com/company/abbvie-inc/news/abbvie-announces-positive-topline-results-from-phase-3-affirm-study-evaluating-skyrizir-risankizumab-subcutaneous-induction-in-patients-with-crohns-disease</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/abbvie-announces-positive-topline-results-from-phase-3-affirm-study-evaluating-skyrizir-risankizumab-subcutaneous-induction-in-patients-with-crohns-disease</guid>
<pubDate>Mon, 02 Mar 2026 13:30:00 GMT</pubDate>
<description>AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating the efficacy and safety of risankizumab (SKYRIZI®) subcutaneous (SC) induction treatment versus placebo in adult patients with moderately to severely active Crohn's disease (CD).1</description>
</item>
<item>
<title>AbbVie to Present at the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/abbvie-inc/news/abbvie-to-present-at-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/abbvie-to-present-at-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Tue, 24 Feb 2026 13:00:00 GMT</pubDate>
<description>AbbVie (NYSE: ABBV) will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026. Management will participate in a fireside chat at 10:10 a.m. Central Time.</description>
</item>
<item>
<title>AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States</title>
<link>https://6ix.com/company/abbvie-inc/news/abbvie-to-invest-dollar380-million-in-north-chicago-to-further-expand-active-pharmaceutical-ingredient-manufacturing-in-the-united-states</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/abbvie-to-invest-dollar380-million-in-north-chicago-to-further-expand-active-pharmaceutical-ingredient-manufacturing-in-the-united-states</guid>
<pubDate>Mon, 23 Feb 2026 16:00:00 GMT</pubDate>
<description>AbbVie (NYSE: ABBV) today announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus. These new state-of-the-art facilities will integrate advanced manufacturing technologies with artificial intelligence (AI) to support the production of AbbVie's next-generation neuroscience and obesity medications.</description>
</item>
<item>
<title>AbbVie Declares Quarterly Dividend</title>
<link>https://6ix.com/company/abbvie-inc/news/abbvie-declares-quarterly-dividend</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/abbvie-declares-quarterly-dividend</guid>
<pubDate>Thu, 19 Feb 2026 14:37:00 GMT</pubDate>
<description>The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share.</description>
</item>
<item>
<title>Facial Injectable Analysis Report 2025: An $18.89 Billion Market by 2029, Driven by New Product Launches, Emerging Markets, AI Innovations, Male Aesthetics, Younger Demographics</title>
<link>https://6ix.com/company/abbvie-inc/news/facial-injectable-analysis-report-2025-153200270</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/facial-injectable-analysis-report-2025-153200270</guid>
<pubDate>Tue, 17 Feb 2026 15:32:00 GMT</pubDate>
<description>Key applications of facial injectables include wrinkle reduction, facial line correction, and enhancement of facial features. The market is segmented by type (Derma Fillers and Neuromodulator Aesthetics), application (Facial Line Correction, Face Lift), and end-users. North America leads the market share due to technological advancements and high consumer awareness, while the Asia Pacific region is expected to witness the fastest growth. Key players like AbbVie, Ipsen, and Galderma are expanding</description>
</item>
<item>
<title>AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/abbvie-inc/news/abbvie-reports-full-fourth-quarter-124800220</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/abbvie-reports-full-fourth-quarter-124800220</guid>
<pubDate>Wed, 04 Feb 2026 12:48:00 GMT</pubDate>
<description>AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2025.</description>
</item>
<item>
<title>AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo</title>
<link>https://6ix.com/company/abbvie-inc/news/abbvie-submits-regulatory-applications-to-fda-and-ema-for-upadacitinib-rinvoqr-in-adults-and-adolescents-with-vitiligo</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/abbvie-submits-regulatory-applications-to-fda-and-ema-for-upadacitinib-rinvoqr-in-adults-and-adolescents-with-vitiligo</guid>
<pubDate>Tue, 03 Feb 2026 13:00:00 GMT</pubDate>
<description>AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ®; 15 mg, once daily) for the treatment of adult and adolescent patients living with non-segmental vitiligo (NSV). The regulatory submissions to the FDA and EMA are supported by previously announced results from the Viti-Up studies evaluating the safety and efficacy of upadacitinib in patients with N</description>
</item>
<item>
<title>AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships</title>
<link>https://6ix.com/company/abbvie-inc/news/abbvie-launches-love-in-mindtm-to-spotlight-the-emotional-impact-of-migraine-on-romantic-relationships</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/abbvie-launches-love-in-mindtm-to-spotlight-the-emotional-impact-of-migraine-on-romantic-relationships</guid>
<pubDate>Thu, 29 Jan 2026 13:00:00 GMT</pubDate>
<description>AbbVie (NYSE: ABBV) announced today the launch of Love in Mind™, an educational initiative that seeks to elevate the conversation about the emotional impact of living with migraine, beyond the physical symptoms, with a focus on dating and romantic relationships. Migraine is more than just a headache. It is an underdiagnosed, undertreated neurological disease that can cause debilitating pain affecting nearly 40 million Americans.1,2</description>
</item>
<item>
<title>AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)</title>
<link>https://6ix.com/company/abbvie-inc/news/abbvie-announces-topline-results-for-epcoritamab-duobodyr-cd3xcd20-from-phase-3-epcorer-dlbcl-1-trial-in-patients-with-relapsedrefractory-diffuse-large-b-cell-lymphoma-dlbcl</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/abbvie-announces-topline-results-for-epcoritamab-duobodyr-cd3xcd20-from-phase-3-epcorer-dlbcl-1-trial-in-patients-with-relapsedrefractory-diffuse-large-b-cell-lymphoma-dlbcl</guid>
<pubDate>Fri, 16 Jan 2026 18:43:00 GMT</pubDate>
<description>AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to investigator's choice of chemoimmunotherapy in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The study demonstrated an improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92])*. Improvements were observed in complete response rates (CRR), durat</description>
</item>
<item>
<title>AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans</title>
<link>https://6ix.com/company/abbvie-inc/news/abbvie-trump-administration-reach-agreement-233000439</link>
<guid isPermaLink="true">https://6ix.com/company/abbvie-inc/news/abbvie-trump-administration-reach-agreement-233000439</guid>
<pubDate>Mon, 12 Jan 2026 23:30:00 GMT</pubDate>
<description>AbbVie (NYSE: ABBV) today announced a voluntary agreement with the Trump administration to further advance access and affordability for Americans while protecting and investing in U.S. pharmaceutical innovation.</description>
</item>
</channel>
</rss>